Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment

BACKGROUND: Second line of treatment of hepatocellular carcinoma (HCC) has notably changed in recent years as three novel drugs with a different mechanism of action have demonstrated to improve survival compared to placebo; thus, there is a need to better define the profile of optimal candidates to...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Oncol
Hauptverfasser: Roviello, Giandomenico, Casadei-Gardini, Andrea, Nobili, Stefania, Mini, Enrico, Fancelli, Sara
Format: Artigo
Sprache:Inglês
Veröffentlicht: Hindawi 2020
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7321521/
https://ncbi.nlm.nih.gov/pubmed/32655640
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/8024124
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge